Review of hepatitis B therapeutics

Debika Bhattacharya, Chloe L Thio

Research output: Contribution to journalArticle

Abstract

Currently, there are 7 approved therapies for chronic hepatitis B virus (HBV) infection, an increase from just 3 agents 5 years ago. This review will focus on the pharmacology, potency, and adverse events associated with immunomodulatory agents and nucleos(t)ide analogues, with an emphasis on targets of therapy within the HBV life cycle. We will also offer guidelines for the use of available anti-HBV agents and review the emerging challenges in hepatitis B management, including HBV drug resistance, its management, and the potential role of combination therapy.

Original languageEnglish (US)
Pages (from-to)1201-1208
Number of pages8
JournalClinical Infectious Diseases
Volume51
Issue number10
DOIs
StatePublished - Nov 15 2010

Fingerprint

Hepatitis B
Hepatitis B virus
Chronic Hepatitis B
Virus Diseases
Therapeutics
Life Cycle Stages
Drug Resistance
Pharmacology
Guidelines

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Review of hepatitis B therapeutics. / Bhattacharya, Debika; Thio, Chloe L.

In: Clinical Infectious Diseases, Vol. 51, No. 10, 15.11.2010, p. 1201-1208.

Research output: Contribution to journalArticle

Bhattacharya, Debika ; Thio, Chloe L. / Review of hepatitis B therapeutics. In: Clinical Infectious Diseases. 2010 ; Vol. 51, No. 10. pp. 1201-1208.
@article{b3b7a5c69df141278e8c5d71bb641fb0,
title = "Review of hepatitis B therapeutics",
abstract = "Currently, there are 7 approved therapies for chronic hepatitis B virus (HBV) infection, an increase from just 3 agents 5 years ago. This review will focus on the pharmacology, potency, and adverse events associated with immunomodulatory agents and nucleos(t)ide analogues, with an emphasis on targets of therapy within the HBV life cycle. We will also offer guidelines for the use of available anti-HBV agents and review the emerging challenges in hepatitis B management, including HBV drug resistance, its management, and the potential role of combination therapy.",
author = "Debika Bhattacharya and Thio, {Chloe L}",
year = "2010",
month = "11",
day = "15",
doi = "10.1086/656624",
language = "English (US)",
volume = "51",
pages = "1201--1208",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Review of hepatitis B therapeutics

AU - Bhattacharya, Debika

AU - Thio, Chloe L

PY - 2010/11/15

Y1 - 2010/11/15

N2 - Currently, there are 7 approved therapies for chronic hepatitis B virus (HBV) infection, an increase from just 3 agents 5 years ago. This review will focus on the pharmacology, potency, and adverse events associated with immunomodulatory agents and nucleos(t)ide analogues, with an emphasis on targets of therapy within the HBV life cycle. We will also offer guidelines for the use of available anti-HBV agents and review the emerging challenges in hepatitis B management, including HBV drug resistance, its management, and the potential role of combination therapy.

AB - Currently, there are 7 approved therapies for chronic hepatitis B virus (HBV) infection, an increase from just 3 agents 5 years ago. This review will focus on the pharmacology, potency, and adverse events associated with immunomodulatory agents and nucleos(t)ide analogues, with an emphasis on targets of therapy within the HBV life cycle. We will also offer guidelines for the use of available anti-HBV agents and review the emerging challenges in hepatitis B management, including HBV drug resistance, its management, and the potential role of combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=78349236621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349236621&partnerID=8YFLogxK

U2 - 10.1086/656624

DO - 10.1086/656624

M3 - Article

C2 - 20954965

AN - SCOPUS:78349236621

VL - 51

SP - 1201

EP - 1208

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 10

ER -